RZLT
Rezolute Inc
NASDAQ: RZLT · HEALTHCARE · BIOTECHNOLOGY
$3.20
+2.56% today
Updated 2026-04-30
Market cap
$293.79M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-0.93
Dividend yield
—
52W range
$1 – $11
Volume
2.4M
Rezolute Inc (RZLT) Earnings
Quarterly earnings history, analyst estimates, and stock price reaction.
EPS beat streak
3 of 8
Last 8 quarters
Avg EPS surprise
-8.4%
Last 4 quarters
Revenue YoY growth
—
Most recent quarter
EPS YoY growth
+0.0%
Most recent quarter
Earnings surprise history (last 12 quarters)
Beat estimate Missed estimate
Quarterly EPS and revenue trend
Quarterly revenue EPS (diluted)
How the stock reacts to earnings
Avg 1-day reaction
+16.7%
Last 2 reports
Positive reaction rate
100%
2 of 2 quarters
Largest single-day move
+18.2%
2026-02-11
| Report date | EPS actual | Surprise | Close before | Close after | 1-day reaction |
|---|---|---|---|---|---|
| 2026-02-11 | $-0.22 | -17.6% | $3.07 | $3.63 | +18.2% |
| 2025-11-06 | $-0.18 | +18.2% | $9.35 | $10.76 | +15.1% |
Quarterly earnings history
| Fiscal quarter ending | EPS estimate | EPS actual | Surprise | Revenue | YoY revenue |
|---|---|---|---|---|---|
| 2025-12-31 | $-0.19 | $-0.22 | -17.6% | — | — |
| 2025-09-30 | $-0.22 | $-0.18 | +18.2% | — | — |
| 2025-06-30 | $-0.21 | $-0.26 | -21.9% | $46000.00 | -20.7% |
| 2025-03-31 | $-0.24 | $-0.27 | -12.5% | — | — |
| 2024-12-31 | $-0.26 | $-0.22 | +15.4% | — | — |
| 2024-09-30 | $-0.33 | $-0.22 | +33.3% | — | — |
| 2024-06-30 | $-0.33 | $-0.44 | -33.3% | $58000.00 | — |
| 2024-03-31 | $-0.30 | $-0.34 | -13.3% | — | — |
| 2023-12-31 | $-0.30 | $-0.27 | +10.0% | — | — |
| 2023-09-30 | $-0.28 | $-0.28 | +0.0% | — | — |
| 2023-06-30 | $-0.36 | $-0.25 | +30.6% | — | — |
Frequently asked questions
Has Rezolute Inc beaten earnings estimates?
Rezolute Inc has beaten Wall Street EPS estimates in 3 of its last 8 quarterly reports, with an average EPS surprise of -8.4% over the last 4 quarters.
How does RZLT stock react to earnings?
RZLT stock has moved an average of +16.7% in the trading day following earnings over its last 2 reports, with positive reactions in 100% of those quarters.